Inozyme Pharma Analyst Ratings
Inozyme Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 211.74% | HC Wainwright & Co. | $19 → $16 | Maintains | Buy |
| 07/27/2023 | 348.12% | Needham | → $23 | Reiterates | Buy → Buy |
| 05/10/2023 | 348.12% | Needham | → $23 | Reiterates | → Buy |
| 04/19/2023 | 348.12% | Needham | → $23 | Reiterates | → Buy |
| 03/23/2023 | 16.9% | Jefferies | $4.5 → $6 | Upgrades | Hold → Buy |
| 03/23/2023 | 348.12% | Needham | → $23 | Reiterates | → Buy |
| 02/17/2023 | 289.67% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/17/2023 | 348.12% | Needham | → $23 | Reiterates | → Buy |
| 05/26/2022 | -2.58% | Jefferies | → $5 | Initiates Coverage On | → Hold |
| 05/11/2022 | 289.67% | HC Wainwright & Co. | $33 → $20 | Maintains | Buy |
| 03/16/2022 | 387.09% | Wedbush | $35 → $25 | Maintains | Outperform |
| 02/07/2022 | 542.96% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 11/29/2021 | 348.12% | Needham | → $23 | Initiates Coverage On | → Buy |
| 08/18/2020 | 581.93% | Wedbush | → $35 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 542.96% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 08/18/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/18/2020 | 679.35% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/04/2023 | 211.74% | HC Wainwright公司 | $19→$16 | 維護 | 買 |
| 07/27/2023 | 348.12% | 李約瑟 | →$23 | 重申 | 購買→購買 |
| 2023年05月10日 | 348.12% | 李約瑟 | →$23 | 重申 | →購買 |
| 04/19/2023 | 348.12% | 李約瑟 | →$23 | 重申 | →購買 |
| 03/23/2023 | 16.9% | 傑富瑞 | $4.5→$6 | 升級 | 持有→購買 |
| 03/23/2023 | 348.12% | 李約瑟 | →$23 | 重申 | →購買 |
| 02/17/2023 | 289.67% | HC Wainwright公司 | →$20 | 重申 | →購買 |
| 02/17/2023 | 348.12% | 李約瑟 | →$23 | 重申 | →購買 |
| 2022年05月26日 | -2.58% | 傑富瑞 | →$5 | 開始承保 | →保留 |
| 2022年05月11日 | 289.67% | HC Wainwright公司 | $33→$20 | 維護 | 買 |
| 03/16/2022 | 387.09% | 韋德布什 | $35→$25 | 維護 | 跑贏大盤 |
| 02/07/2022 | 542.96% | HC Wainwright公司 | →$33 | 開始承保 | →購買 |
| 2021年11月29日 | 348.12% | 李約瑟 | →$23 | 開始承保 | →購買 |
| 2020/08/18 | 581.93% | 韋德布什 | →$35 | 開始承保 | →跑贏大盤 |
| 2020/08/18 | 542.96% | B of A證券 | →$33 | 開始承保 | →購買 |
| 2020/08/18 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2020/08/18 | 679.35% | 派珀·桑德勒 | →$40 | 開始承保 | →超重 |
What is the target price for Inozyme Pharma (INZY)?
Inozyme Pharma(Inzy)的目標價是多少？
The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $16.00 expecting INZY to rise to within 12 months (a possible 211.74% upside). 8 analyst firms have reported ratings in the last year.
納斯達克(INZY)的最新目標價是由HC Wainwright&Co.於2023年8月4日報道的。這家分析公司將Inzy的目標價定為16美元，預計Inzy將在12個月內上漲(可能上漲211.74%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Inozyme Pharma (INZY)?
Inozyme Pharma(Inzy)的最新分析師評級是多少？
The latest analyst rating for Inozyme Pharma (NASDAQ: INZY) was provided by HC Wainwright & Co., and Inozyme Pharma maintained their buy rating.
對Inozyme製藥公司(納斯達克代碼：INZY)的最新分析師評級由HC Wainwright&Co.提供，Inozyme製藥公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?
Inozyme Pharma(Inzy)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Inozyme Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Inozyme Pharma的上一次評級是在2023年8月4日提交的，因此您應該預計下一次評級將在2024年8月4日左右提供。
Is the Analyst Rating Inozyme Pharma (INZY) correct?
分析師對Inozyme Pharma(Inzy)的評級正確嗎？
While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a maintained with a price target of $19.00 to $16.00. The current price Inozyme Pharma (INZY) is trading at is $5.13, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Inozyme Pharma(Inzy)評級維持不變，目標價在19.00美元至16.00美元之間。Inozyme Pharma(Inzy)目前的交易價格為5.13美元，超出了分析師的預測區間。